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INTRODUCTION
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition during pregnancy and is associated with several maternal and neonatal complications (1, 2) . Less in known about the economic burden of the disease; with only one cost of illness study found in the literature. That study estimated the healthcare costs of GDM in the United States of America (USA) to be $636 million in 2007 (3).
Screening practices vary within and across European countries with some offering universal screening to all pregnant women and others only to selective high risk groups. The results from Australian Carbohydrate Intolerance in Pregnant Women (ACHOIS) Study showed that active treatment of glycaemia was both an effective and cost effective strategy for women with impaired glucose tolerance and GDM (2, 4) . This has led to calls for a more aggressive approach to screening. In Ireland, there is no national policy on GDM screening and a debate
continues as to what form such a policy should take.
In the west of Ireland, the Atlantic Diabetes in Pregnancy (ATLANTIC DIP) network provides universal testing for all pregnant women at 24-28 weeks using a 75g Oral Glucose Tolerance Test (OGTT) (5) . The ATLANTIC DIP network was established in 2005 with a focus on research, audit, clinical care, professional and patient education and to provide robust information on pregnancy outcomes in women with diabetes. The network includes five hospital centres along the Atlantic seaboard which are linked using a clinical information database which captures a comprehensive range of data on maternal characteristics, outcomes for mothers and infants, and healthcare resource usage over the course of pregnancy. Ethical approval for the project was provided by the Health Service Executive Research Ethics
Committee.
In this study, we combine data for a cohort of women from the database with additional data on resource use and unit costs to estimate the costs associated with screening, testing for and treatment of GDM over the course of pregnancy. We extrapolate these results to the national level to estimate the costs associated with implementing a strategy of universal screening in Ireland.
PATIENTS AND METHODS
Overview
We use a bottom-up, prevalence-based method of analysis using data from a range of regional, national and international sources. Estimates for GDM prevalence, maternal and neonatal outcomes, and healthcare resource utilisation associated with the care pathway followed were obtained from an ATLANTIC DIP dataset and extrapolated using national statistics for the annual number of eligible pregnancies. It was assumed for the base-case analysis that prevalence among women who did not participate in testing was equal to that observed among those who were tested. Furthermore, a distinction was made between women whose condition was detected and treated and women who, having declined testing, went undetected and untreated. To reflect expected differences in mode of delivery and neonatal admissions across detected and undetected cases, observed utilisation rates for a combined sample of negative tested cases and non participants in the screening programme were adopted to cost the latter. This approach assumes that the selected group is representative of the general population of pregnant women and that mode of delivery and neonatal care for undetected cases follows that of the general population.
The episode of care to which the cost analysis related covered the period from screen offer until discharge following delivery. Activities were examined under five headings: (i) screening and testing, (ii) GDM treatment, (iii) prenatal care, (iv) delivery care, and (v) neonatal care. The cost per individual activity was estimated, totalled and all costs aggregated to provide an estimate of the total cost of care which was then extrapolated to the national level. Resource use was identified from a variety of sources including interviews with consultants at representative ATLANTIC DIP centres, published national data and, when necessary, published UK data sources. In cases where UK treatment protocols were adopted, these were reviewed by the study clinicians to ensure that they were applicable to the Irish setting. A vector of unit costs was applied to estimate the cost associated with each activity.
Unit cost data were obtained from national sources, and where necessary UK sources. Where the latter were used they were transformed into Euros in 2008 prices using appropriate inflation and exchange rate indices (6, 7) . A series of one-way and probabilistic analyses were undertaken to explore the uncertainty in the analysis.
Costing Methodology
The approach taken to cost each individual healthcare activity is detailed below and in Table   1 with further information provided in the appendix.
(i) Screening and Testing
We assume that all eligible pregnant women were offered testing. The annual number of singleton pregnancies in Ireland in 2008 was obtained from the Central Statistics Office (8).
Women with a multiple births were excluded from the analysis because the small numbers involved would make it difficult to calculate the additional cost attributable to diabetes in a robust manner. Furthermore, pregnancies where screening would not be offered due to the existence of prior complications (20% of total pregnancies) were excluded from calculations as these cases would already be under surveillance (9) . (ii)
GDM Treatment
Prevalence in the participant group in ATLANTIC DIP was 2.6% (Criteria: fasting blood glucose >/= 7 mmol/l and/or 2h post glucose load of >/=11.1 mmol/l). For the analysis, this prevalence rate was applied to both participants and non participants in the screening programme. This assumption was made in the absence of data on the actual number of GDM cases within the non participant cohort.
Treatment for detected cases of GDM included lifestyle intervention and blood glucose self monitoring. In costing the lifestyle intervention, we assumed that all women attended a consultation with a dietician and two consultations with a diabetes nurse specialist (consistent with the treatment protocol operated in the ATLANTIC DIP). The estimated cost of lifestyle intervention was €205 per case, based on the cost of the nurse time input. In costing self monitoring, we assumed that all cases self-monitored for an average of twelve weeks, testing their blood sugar level on average four times per day. The combination of lancets, strips and blood glucose meter for a standard case were adopted from a UK study (9) , giving an estimated cost €144.20 per case. In addition, women who did not respond to lifestyle intervention after two weeks were prescribed insulin for the remainder of their pregnancy.
The numbers in this category were identified from the study. We assumed that such women received treatment for an average of 90 days. The size, frequency and length of dosage were adopted from a UK study (9) and unit costs for the most commonly prescribed regular insulin and rapid-acting insulin analogues Lispro and Aspart in Ireland were obtained from the Monthly Index of Medical Specialities (10). The average cost of insulin was estimated at €115.07 per case treated.
(iii) Prenatal Care
In respect of prenatal care, data on utilisation of services for both GDM and non-GDM pregnancies were provided by consultants at University College Hospital Galway, a representative ATLANTIC DIP centre. Prenatal care for detected cases was provided in multi-disciplinary clinics by specialists in diabetes and obstetrics. Prenatal care for undetected cases was assumed to follow that of a non-GDM pregnancy. The estimated costs of prenatal care per case were €3195 for GDM cases and €1585 for non-GDM/unidentified GDM cases, based on the specified usage of outpatient clinic consultations, ultrasound scans, and primary care consultations.
(iv) Delivery Care
Mode of delivery was recorded as normal vaginal delivery (NVD) or caesarean section (CS) (no distinction was made between emergency and elective CS). For undetected GDM cases, the observed rates for the combined group of negative tested cases and non participants in the screening programme for CS and NVD were adopted. The respective rates for detected versus undetected cases were 43% and 76% for NVD, and 57% and 24% for CS. The cost per mode of delivery was estimated as the weighted average of all diagnosis related groups (DRG) per mode (weighted on the basis of the number of cases per DRG) in the Health Service Executive Casemix database (11). Estimates of €2373 per NVD case and €5765 per CS were adopted for the analysis.
(v) Neonatal Care
All admissions of infants born to women with GDM to neonatal intensive care were recorded in the database. For undetected cases, the observed rates for neonatal admission for the combined group of negative tested cases and non participants in the screening programme were adopted. The respective rates for detected versus undetected cases were 39% and 11%.
The weighted average cost (€7115) across all neonatal DRG admission categories (11) was adopted for the analysis.
Sensitivity Analysis
A series of one-way sensitivity analyses were undertaken to explore the uncertainty in the base-case analysis. First, of the total number of women offered testing, 58% took up the offer. We explore alternative participation rates of 50%, 65%, 80%, 90% and 100%. Second, as prevalence was estimated for a sample of women in the west of Ireland, it may be the case,
given the region's socio-economic and ethnic make-up, that national prevalence is greater.
We adopt the estimated prevalence rate for England and Wales of 3.5% (9) . Third, as detailed in Table 2 , differences existed across the characteristics of participants and non participants in the screening programme. As a result, there is a possibility of selection bias among the participating group in terms of disease prevalence. We explore the impact of assuming hypothetical higher (5%) and lower (1%) prevalence rates for the non participant group.
Fourth, we assumed that the sensitivity and specificity rates for the 75g OGTT were both 100% (9) . We explore the impact of individually reducing both sensitivity and specificity rates to 50%. We also re-estimate results for assumed rates for sensitivity and specificity of 86% and 80% respectively, as adopted in a previous US study (1) . Finally, observed rates for a combined sample of negative tested cases and non participants were adopted to cost undetected cases. This approach may be considered conservative as it assumes that undetected cases are equivalent to the general population. In sensitivity analysis, we test a potentially upper bound estimate whereby observed rates for detected cases from the ATLANTIC DIP were adjusted using data from the ACHOIS study (2) . The respective rates tested for NVD, CS and neonatal admission for undetected cases were 40%, 60% and 34%.
In addition, uncertainty was explored using probabilistic methods (12,13), whereby input parameters were assigned appropriate probability distributions and a Monte Carlo simulation process was undertaken to generate 1,000 replications of the total cost results. This enabled the estimation of 95% confidence intervals for the total cost estimates.
RESULTS
The results from the base-case analysis are presented in Tables 3. From an The results from the one-way sensitivity analyses are presented in Table 4 . The effect of increasing uptake rates was to increase the total cost of care relative to the base-case analysis, whereas a reduced uptake rate led to reduced costs. Increasing prevalence rates led to increases in the total cost estimates while reducing the prevalence rate for non participants led to a reduction in cost. Reducing the assumed sensitivity and specificity of the 75g OGTT to 50% led to an increase and decrease in the total cost estimate respectively. The effect of assuming respective sensitivity and specificity rates of 86% and 80% led to an increase in the total cost estimate. Finally, adopting upper bound estimates for NVD, CS and neonatal admission for undetected cases led to an increase in the total cost of care.
DISCUSSION
This study provides the first estimates of the healthcare costs associated with GDM in
Ireland. We present estimates in terms of a national universal screening programme, in the increases the medical cost of pregnancy by an average of $3,305 in the USA. Importantly, we made no attempt to monetise the adverse outcomes experienced by mothers and infants which result from untreated GDM or the improved quality of life associated with the provision of appropriate care (2) . To address the broader issue of the cost effectiveness of universal screening, further research is required to relate the costs to the benefits which would result, both in terms of maternal and neonatal outcomes, from the identification and appropriate treatment of GDM (2) . Moreover, these outcomes should be compared to those from the alternative available screening models which could be introduced. For example, recent NICE guidance in the UK recommends that GDM screening be targeted at specific high risk groups
The results from the sensitivity analysis indicate that increasing screening uptake rates would increase the costs of care, primarily as a result of the additional costs of testing and treatment for newly detected cases. As expected a higher overall prevalence rate led to increased costs.
Potential selection bias with respect to screening participation was examined by assuming different prevalence rates for non participants. Higher and lower rates were examined as it was unclear whether non participants were at higher or lower risk than participants.
Increasing the prevalence rate led to an increase in the total costs of care due to the additional costs associated with the care of undetected GDM cases. As expected, reducing the prevalence rate led to a reduction in total costs. While the 75g OGTT is deemed to have high sensitivity and specificity (9), the effect of varying these rates was examined. A reduced sensitivity rate of 50% led to an increase the projected number of GDM cases to be included in the analysis, leading to an increase in the total costs of care. Conversely, a reduced specificity rate of 50% led to a decline in the projected number of GDM cases and a reduction in total costs. An analysis assuming sensitivity and specificity rates of 86% and 80% respectively showed an overall increase in total cost. Finally, adjusting utilisation rates using data from the ACHOIS study led to an increase in the total cost of care for undetected GDM cases.
There were a number of limitations in the analysis which relate directly to the assumptions adopted. Firstly, while we explore the impact of varying prevalence rates for non participants in sensitivity analysis, it is unclear whether the assumptions adopted in the analysis are appropriate in the absence of data on the actual number of GDM cases within this cohort.
Secondly, the applicability of utilisation rates for the combined sample of negative tested cases and non participants in the costing of care for undetected GDM cases is open to question. Nonetheless, we believe this sample to be representative of the general population of pregnant women as it includes both actual and potentially negative cases as well as potentially positive cases not identified and treated for GDM. Thirdly, our results are likely to underestimate the total cost of GDM, as we exclude healthcare resource utilisation post hospital discharge, private out-of-pocket expenses to the woman and her family, and additional losses to broader society. Furthermore, we make no attempt to monetize the adverse effects of GDM on the health of either mother or infant. This is particularly relevant for women with GDM who do not receive appropriate treatment. Moreover, in applying the adopted GDM classification criteria we exclude from the analysis women with impaired glucose tolerance. Fourthly, the process of conducting cost analysis in Ireland is complicated by the lack of nationally available healthcare utilisation and unit cost data. In some cases we adopted equivalent UK data to detail the process and cost of the treatment as Irish data were not readily available. While this is not ideal, appropriate adjustments were made and we endeavoured at all times to be conservative in the assumptions adopted.
Conclusion
This study provides estimates of the healthcare costs associated with universal screening for GDM in Ireland. To address the broader issue of cost effectiveness, a comprehensive economic evaluation is required to compare universal screening to the alternative available screening models which could be introduced in the Irish setting. The current analysis provides information useful to future research that examines this question, further it contributes to the international literature on costs of GDM by providing data on these as they arise in an Irish setting. 
Screening and Testing for Gestational Diabetes
The offer process involved contacting, informing and inviting the individual for a test. The cost per offer (phone call and 15 minutes of clinic secretarial time) is estimated at €3.65 (Table 1 ). The cost per 75 OGTT included clinician time, test materials and laboratory analysis and is estimated at €35.20 (Table 2 ). We assume that the 75 g OGTT has a sensitivity and specificity of 100%; in other words that no false-positive or false-negative results will be obtained. 
Treatment for Gestational Diabetes
We assume that all positive GDM cases received lifestyle intervention and undertook self monitoring using blood glucose monitoring equipment. Those for whom lifestyle intervention was deemed ineffective were treated with insulin.
In costing the lifestyle intervention, we assume that all women attend one consultation with a dietician and two consultations (2 nd for dietary review) with a diabetes nurse specialist. The cost of lifestyle intervention is estimated at €205 (Table 3) . In costing self monitoring, we assume that all positive cases self-monitor for an average of 12 weeks, testing their blood sugar level on average four times per day. The combination of lancets, strips and blood glucose meter and the unit costs for these resource items were adopted from a UK study (9) and were transformed to Euros in 2008 prices using appropriate inflation (6) and exchange indices (7) . The cost of self monitoring is estimated at €144.20 (Table 4) . In costing insulin therapy, we assume that all women received treatment for an average of 90 days. The size, frequency and length of dosage were adopted from a UK study (9) . The unit costs for the most commonly prescribed regular insulin and rapid-acting insulin analogues lispro and aspart were obtained from the Monthly Index of Medical Specialities (MIMS)
Ireland. The cost of insulin is estimated at €115.07 (Table 5) . 
Prenatal Care -Healthcare System Contacts
Pregnant women regularly attend prenatal care services over the course of their pregnancy.
Evidence on healthcare resource usage for both GDM and non-GDM pregnancies was provided by consultants at University College Hospital Galway, which is a representative ATLANTIC DIP centre. The healthcare resource use, unit cost and total cost of care are provided in Table 6 for GDM cases and in Table 7 for non-GDM cases. Prenatal care for the former is estimated at €3195 and for the latter is estimated at €1585. 
Mode of Delivery
We categorise mode of delivery for infants of women with GDM into vaginal delivery and caesarean section. The cost per mode of delivery is estimated as the weighted average across all diagnosis related group (DRG) categories per mode. The estimated cost per mode of delivery is shown in Table 8 . 
Neonatal Care
Infants of women with GDM should be kept with their mothers unless there is a clinical complication or there are abnormal clinical signs that warrant admission for intensive or special care (7) . The ATLANTIC DIP provides data on admissions for infants of women with GDM to the neonatal ward. The cost per neonatal admission is estimated as the weighted average across all neonatal DRG admission categories he estimated cost per neonatal admission for infants of women is shown in Table 9 . 
ACHOIS Outcome Data
As a substantial proportion of women declined or accepted and failed to attend for testing, there will be a cohort of women with GDM who are not identified as being at risk and will not be treated accordingly. While this will result in cost savings in the short term arising from avoided treatment expenditures, there will be longer term effects in terms of adverse outcomes and the healthcare resource implications which result. In particular, we focus the healthcare resources relating to delivery and neonatal care. To reflect the differences in women with GDM who are and are not treated for GDM, we adjust the observed data for treated GDM cases using data from the Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Study (2) . The ACHOIS study was a randomised controlled trial examining the efficacy of treatment for GDM and impaired glucose tolerance in Australia. Data for elective caesarean sections, emergency caesarean infections, and neonatal admissions were adopted from ACHOIS as a measure of effectiveness of treatment for GDM versus non treatment. The observed rates from the ATLANTIC DIP for caesarean sections, vaginal deliveries, and neonatal admissions were adjusted using this data to reflect the fact that women, if positive for GDM, did not receive treatment. An important assumption in this regard is that the treatment regime in Ireland reflects that of Australia. This process is outlined in detail in Table 10 . 
Probabilistic Analysis
Uncertainty associated with the input parameter data is addressed through probabilistic sensitivity analysis. This process involved three steps: Firstly, input parameters in the analysis were assigned appropriate probability distribution. The nature of data used in health economic analysis is such that only a relatively small number of alternative distributions are available (13). These include beta distributions for those parameters which are bounded by an interval between 0 and 1, such as probability. In addition, normal or Gaussian distribution, or alternatively, if the original data is skewed, Gamma or lognormal distributions may be assigned to represent resource use and unit cost data. Table 11 outlines the probability distributions assumed for each parameter in the probabilistic analysis. In respect of unit costs, a Gaussian distribution was specified. In cases where no information was available on the variance of the unit cost, a coefficient of variation equal to 0.40 was used to relate the variance to the mean value. Although 0.40 is an arbitrary value, it was chosen to give quite a large variance, and therefore, vague prior for the unit cost parameter. In respect of resource use, a beta distribution was specified in cases where resource use was modelled using probabilities. The beta distribution, using the methods of moments approach, was also used employed to model uncertainty surrounding data from the ACHOIS study. The second stage of the probabilistic analysis was to propagate the uncertainty for all of the input parameters through the model simultaneously. This process was undertaken using Monte Carlo simulation which re-runs the model a large number of times, with each simulation involving a random draw for a value from each of the input parameter distributions. This process generated a large number of cost results which reflect the combined parameter uncertainty in the analysis. The Monte Carlo simulation was set to 1,000 for the probabilistic model, effectively replicating the analysis 1,000 times. The third step was to present the simulated results in an appropriate format. In this case, the probabilistic model generated 1,000 data points which were used to estimate 95% confidence intervals around the cost estimates of interest. 
